Let’s look on the bright side of things… 1.
Post# of 155577
(Total Views: 777)
Posted On: 10/06/2021 9:38:25 AM
Let’s look on the bright side of things…
1. We have non Amarex trials in Brazil.
2. These Brazil trials have quality partners. In Both CRO and the pharmaceutical company Biomm. We just sit back and watch and these experienced companies do everything we need for approval(s).
3. Today is the day we get the monkey off our back. The 13d group judged to be not included on the Ballot (we hope).
4. That we have a world class law firm pursuing our legal issues. This bodes well for success.
5. That ohm20 makes a very good prediction of just doing a phase 3 for monotherapy could possibly complete inside of a year with much higher sales of 7 billion than combo at 1 billion limited revenue. Besides nobody would use combo after mono is approved. No need to.
6. That shareholders meeting settled and only issue being with request of shares of 200 million that will give us strength to buy the volume of batch size of Leronlimab from Samsung to sell and kick start our sales to become a much quicker manufacturing process. With sales potentially across the world. With EUA’s in Brazil.
Things are still moving forward and all is not bad and hopefully it is just format issue and tomorrow’s ruling for the injunction to open all access to our data is granted and a quality CRO can format it properly for all trials … if all are compromised. The issues may have already been fixed by Amarex already. They have had time to save their own reputation (what’s left of it) and hopefully they did just that.
1. We have non Amarex trials in Brazil.
2. These Brazil trials have quality partners. In Both CRO and the pharmaceutical company Biomm. We just sit back and watch and these experienced companies do everything we need for approval(s).
3. Today is the day we get the monkey off our back. The 13d group judged to be not included on the Ballot (we hope).
4. That we have a world class law firm pursuing our legal issues. This bodes well for success.
5. That ohm20 makes a very good prediction of just doing a phase 3 for monotherapy could possibly complete inside of a year with much higher sales of 7 billion than combo at 1 billion limited revenue. Besides nobody would use combo after mono is approved. No need to.
6. That shareholders meeting settled and only issue being with request of shares of 200 million that will give us strength to buy the volume of batch size of Leronlimab from Samsung to sell and kick start our sales to become a much quicker manufacturing process. With sales potentially across the world. With EUA’s in Brazil.
Things are still moving forward and all is not bad and hopefully it is just format issue and tomorrow’s ruling for the injunction to open all access to our data is granted and a quality CRO can format it properly for all trials … if all are compromised. The issues may have already been fixed by Amarex already. They have had time to save their own reputation (what’s left of it) and hopefully they did just that.
(14)
(0)